The global lateral flow assay (LFA) market is projected to grow from USD 10.01 billion in 2024 to USD 15.42 billion by 2030, driven by increasing demand for point-of-care testing and the rising ...

In a study published today in Biofunctional Materials, Prof. Dr. Haidar, Founder and CEO of BioMAT’X I+D+I LABs in Santiago, Chile, explores a new era in healthcare diagnostics driven by ...

Changes in healthcare economics are clearly having an impact on point-of-care (POC) diagnostic testing. Market demand for remote testing is driving companies to develop easy-to-use platforms versus ...

Study of the evolution of PoC testing shows that technology development has progressed to be close to laboratory quality and to meet the clinical needs. In the past, simple chemical test methods were ...

The global market growth reflects increasing adoption across hospitals, clinics, home-care settings, and remote healthcare environments. Infectious disease testing dominates the market, accounting for ...

Polymerase chain reaction (PCR) tests are one of the most popular diagnostic tools for the detection and diagnosis of viral diseases, such as coronavirus (COVID-19), due to their ability to rapidly ...

Lateral flow assays, also called immunochromatographic assays, identify or measure biomolecules in intricate samples like blood, saliva, urine, or other fluids to diagnose numerous medical conditions.

Infectious diseases afflict millions of people every year. These hard-hitting viruses can rapidly sweep through populations and, in some cases, whole continents in a matter of weeks. Identifying and ...

Can you provide a definition of point-of-care diagnostics in veterinary medicine? These are diagnostic devices that are portable and employed at the location where a patient presents. This is very ...